FDA warned website buycodeine.us for selling unapproved, misbranded opioid and stimulant drugs online without prescriptions.
What happened
FDA reviewed the website www.buycodeine.us and found it offering Toseina (codeine phosphate hemihydrate oral solution) and Ritalina (methylphenidate hydrochloride tablets) to U.S. consumers. FDA said there are no approved applications for these products and that the site offers prescription drugs without a prescription.
What FDA found
The website sold Toseina and Ritalina as unapproved new drugs (drugs without FDA approval) with no FDA-approved application.
FD&C Act sections 301(d), 505(a) [21 U.S.C. §§ 331(d), 355(a)]The labeling for these prescription drugs did not give adequate directions for safe use by a layperson, so FDA calls them misbranded.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]The website offered prescription drugs for sale without a prescription from a licensed healthcare practitioner.
FD&C Act sections 503(b)(1), 301(k) [21 U.S.C. §§ 353(b)(1), 331(k)]
What FDA wants
FDA asks the company to stop offering unapproved and misbranded drugs to U.S. consumers and to notify FDA in writing within 15 working days describing corrective steps and how it will prevent recurrence.
Who should pay attention
- companies selling prescription drugs online to U.S. consumers
- brands and distributors of opioid or stimulant products
- platforms hosting online pharmacy storefronts
This is a summary. Read the original letter on fda.gov.